SALT LAKE CITY, July 28, 2023 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Twistle® by Health Catalyst (Twistle), a leading clinical workflow and patient engagement platform, has met certain key regulatory, security and privacy requirements necessary for earning HITRUST certification.
HITRUST leverages nationally and internationally accepted standards including ISO, NIST, PCI, HIPAA, and others to ensure a comprehensive set of baseline security controls. HITRUST CSF Certified status demonstrates that Twistle by Health Catalyst has met HITRUST's framework that assessed compliance with certain key regulations and industry-defined requirements that collectively aim to appropriately manage security and privacy risk.
"Health Catalyst is pleased to have achieved HITRUST's CSF Certification for Twistle," said Kevin Scharnhorst, CISSP, CISM, CPHIMS, Chief Information Security Officer at Health Catalyst. "We are committed to maintaining industry best practices for information security and data privacy, critical for protecting our clients and our mission."
Health Catalyst's HITRUST CSF-Certified and applicable platforms are:
About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
Media Contact:
Amanda Hundt
This email address is being protected from spambots. You need JavaScript enabled to view it.
575-491-0974
Last Trade: | US$7.70 |
Daily Change: | -0.34 -4.23 |
Daily Volume: | 376,672 |
Market Cap: | US$465.620M |
August 27, 2024 August 08, 2024 August 08, 2024 August 07, 2024 May 21, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB